# Bioventus Receives FDA 510(k) Clearances for TalisMann and StimTrial Peripheral Nerve Stimulation Devices

> fda · REPORTED · 2025-07-01

Bioventus received FDA 510(k) clearances for both its TalisMann and StimTrial peripheral nerve stimulation (PNS) devices in July 2025, expanding its portfolio of non-opioid, minimally invasive therapies for chronic pain management. These clearances position the company to offer a comprehensive PNS portfolio from initial patient assessment to long-term therapy.

About Bioventus: Bioventus is a medical device company specializing in non-opioid orthobiologic and neuromodulation therapies, including peripheral nerve stimulation systems for chronic pain, serving orthopedic surgeons and pain management physicians.

- Company: Bioventus
- Sector: medical devices
- Primary source: https://www.sec.gov/Archives/edgar/data/1665988/000149315225023846/bvs-20251231.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.